Doctor Matthew Blunt

Dr Matthew Blunt

Senior Research Fellow

Accepting applications from PhD students.


Dr Matthew Blunt leads a research team focused on natural killer (NK) cells, novel cancer immunotherapies and haematological malignancies. His research group interacts closely with haematologists at the University Hospital Southampton and with international collaborators from both academia and industry.

Examples of published research include:

  • Lymph node associated signals inhibit NK activation against leukemic cells via the immune checkpoint NKG2A (Fisher JG et al, Leukemia, 2023)
  • KIR2DS2 expression identifies NK cells with enhanced anti-cancer activity (Blunt MD et al, Journal of Immunology, 2022)
  • XPO1 inhibition stimulates NK cell activation against lymphoma cells (Fisher JG et al, Frontiers in Oncology, 2021).
  • Development of a novel therapeutic to activate NK cells against cancer (Rettman P, Blunt MD et al, Journal for immunotherapy of cancer, 2021).
  • Targeting the PI3K/mTOR pathway in leukaemia (Blunt MD et al, Blood, 2015).
  • Identification of IL-4 as a resistance mechanism to idelalisib and ibrutinib in leukaemia (Aguilar-Hernandez M, Blunt MD et al, Blood, 2016 *Co-first author).
  • Preclinical evaluation of the dual SYK/JAK inhibitor cerdulatinib alone and in combination with venetoclax in leukaemia (Blunt MD et al, Clinical Cancer Research, 2016).